ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of September 9, 2024, at 5:00 P.M. This form is a registration statement that allows companies to issue various securities to the public. The effectiveness of this form indicates that ZyVersa Therapeutics has met all the necessary regulatory requirements to proceed with the issuance of securities, which could include stocks, bonds, or other types of financial instruments. The SEC's notice of effectiveness is a standard procedure that signifies the company can now move forward with its plans to raise capital through the securities market.

ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of September 9, 2024, at 5:00 P.M. This form is a registration statement that allows companies to issue various securities to the public. The effectiveness of this form indicates that ZyVersa Therapeutics has met all the necessary regulatory requirements to proceed with the issuance of securities, which could include stocks, bonds, or other types of financial instruments. The SEC's notice of effectiveness is a standard procedure that signifies the company can now move forward with its plans to raise capital through the securities market.